Reimagining the Clinician + AI Partnership

AI in behavioral health

As someone who has spent years in the trenches of behavioral health leadership, I’ve watched our field wrestle with an increasingly complex challenge: how do we provide the personalized, comprehensive care our patients deserve when our time and resources are stretched impossibly thin?

The average behavioral health clinician today is carrying an impossible workload. Between crafting individualized treatment plans, documenting patient interactions, monitoring medication adherence, tracking patient progress, and managing administrative requirements, we’re asked to be part clinician, part data analyst, part administrative coordinator, and part mind reader.

The Human at the Center, with AI as a Collaborative Partner

AI is not a magic solution. What I’m proposing is something more nuanced: AI as a collaborative partner that augments our clinical expertise rather than attempting to replace it.

Imagine an AI assistant that doesn’t just crunch numbers, but actually understands the intricate landscape of behavioral health. A tool that could:

  • Analyze treatment histories of similar patients to help inform personalized care strategies
  • Automatically draft comprehensive, accurate clinical notes that capture the nuance of each patient interaction
  • Proactively flag potential medication interactions or side effects based on real-time patient data
  • Help track patient progress between appointments, identifying early warning signs that might otherwise go unnoticed

This is about giving clinicians superpowers – the ability to see patterns, anticipate needs, and spend more quality time doing what we entered this field to do: truly connect with and help their patients.

The Workflow Revolution Goes From Administrative Burden to Clinical Insight

How many hours do we lose each week to paperwork that takes us away from patient care? Current estimates suggest clinicians spend nearly 50% of their time on documentation and administrative tasks.

An AI partnership could fundamentally transform that equation. By automating documentation, providing predictive insights, and streamlining patient monitoring, we could reclaim those hours and redirect them toward meaningful clinical interactions.

Building Trust is The Critical Human Element

What I can hear from many clinicians – “Another tech solution that doesn’t understand the complexity of what we do.” And you’re right to be skeptical. The most successful AI tools won’t be developed in a tech bubble, but through deep collaboration with clinical professionals who understand the intricate dance of patient care. I co-founded Videra in part for this reason specifically – so I can help be that clinical voice in the room as we develop tools to help other clinicians.

This means AI development must be:

  • Transparent about capabilities and limitations
  • Rigorously tested in real-world clinical environments
  • Designed with robust privacy and ethical considerations
  • Continuously refined through clinician feedback

An Invitation to Collaborate

Technology isn’t replacing human connection. Technology enhances our capacity for connection. As someone who has led clinics and understands the daily challenges clinicians face, I see immense potential in a thoughtful, collaborative approach to AI integration.

For my fellow clinicians, what are your hopes? Your concerns? Your vision for how technology can support the incredible work we do?

The future of behavioral health isn’t about choosing between human expertise and technological innovation. It’s about creating a partnership that amplifies our most fundamental goal: providing compassionate, personalized care that truly helps our patients thrive.

What are your thoughts? Join me on LinkedIn to discuss.

Check our blog for the latest discussions on AI n healthcare, behavioral health, and pharma.

Take me to the blog

Why We Made TDScreen Free: A CEO’s Perspective on Democratizing Mental Health Screening

TDScreen AI-powered TD screening tool interface showing patient assessment dashboard

Last week we announced the launch of TDScreen – our AI-powered Tardive Dyskinesia (TD) screening tool. The response has been immediate and overwhelming, validating everything we believed about the urgent need for accessible TD screening.

This is exactly why we built TDScreen.

The Hidden Crisis in Plain Sight

Let me share some numbers that keep me up at night:

  • At least 500,000 Americans suffer with Tardive Dyskinesia
  • Only 20% of those  have been diagnosed
  • That’s a 80% diagnosis gap

But here’s what those statistics don’t capture: Each untreated case represents someone whose involuntary movements might be dismissed as nervousness, aging, or “just a quirk.” Someone who might stop taking life-changing medications because they’re embarrassed by movements that could be managed. Someone whose quality of life is quietly deteriorating while effective treatments exist.

Why Traditional Screening Fails

The standard AIMS assessment takes 15-20 minutes of specialized clinical time. For a psychiatrist seeing 20-30 patients daily, screening everyone quarterly (as guidelines recommend) is mathematically impossible. It’s not about clinician dedication – it’s about the brutal reality of time constraints in modern healthcare.

This is where AI changes everything. TDScreen compresses expert-level assessment into a 5-minute patient self-assessment, with accuracy that actually exceeds human raters (0.89 AUC, validated in our Journal of Clinical Psychiatry study).

The Business Decision to Make TDScreen Free

We’re not in the business of gatekeeping essential healthcare tools. We’re in the business of transforming behavioral health outcomes.

Making TDScreen free isn’t charity – it’s strategy. Every provider who adopts TDScreen becomes part of our mission to modernize behavioral healthcare. Every patient who gets screened is a potential life improved. And every success story builds the foundation for our broader platform vision.

What Our TD Screening Tool Actually Does

For providers wondering about the specifics – here’s exactly what you get:

Immediate Clinical Value

  • Patient completes video assessment (smartphone, tablet, or computer)
  • AI analyzes movement patterns based on AIMS criteria
  • You receive an objective risk score with visual highlights
  • Track changes over time with quantitative data

Zero Hidden Costs

  • No subscription fees
  • No per-patient charges
  • No training requirements
  • No IT integration needed
  • Start screening in under 15 minutes

The Evidence Behind TDScreen

Our research, published yesterday in the Journal of Clinical Psychiatry, demonstrates that TDScreen achieves:

  • Superior consistency compared to human raters (Cohen’s Kappa of 0.61)
  • Validated across 350+ patients in multi-site clinical trials

This isn’t theoretical – it’s proven technology ready for clinical use today. Our partners in the study – Dr. Anthony A. Sterns, Ph.D., lead researcher on the project and CEO at iRxReminder, Dr. Owen Muir, CMO of iRxReminder, CMO and co-founder of Radial Health, and co-author of the publication, and the National Institutes of Health – provided the data and analysis that helped to create TDScreen.

The Bigger Vision

Why This TD Screening Tool Changes Everything

TDScreen is just the beginning. At Videra Health, we’re building a comprehensive AI platform that transforms how behavioral health providers deliver care. But we started with TD screening for a reason: it’s a massive, solvable problem where AI demonstrably outperforms traditional methods.

By making TDScreen free, we’re proving that AI in healthcare doesn’t have to be expensive, complex, or intimidating. It can be as simple as sending your patient a link.

Your Patients Are Waiting

If you prescribe antipsychotics, you have patients at risk for TD. Statistically, several already have symptoms. The question isn’t whether to screen – it’s whether you’ll do it the old way or the better way.

TDScreen is live, validated, and free at tdscreen.ai.

No sales calls. No demos required. No contracts to sign.

Just better care, starting today.

Join the Movement

In healthcare innovation, the best time to adopt new technology is when it’s proven but not yet universal. TDScreen has the validation (peer-reviewed research), the accessibility (completely free), and the simplicity (5-minute assessments) to transform TD screening.

The providers who adopt TDScreen today aren’t just using a tool – they’re setting a new standard of care for their patients.

Will you join us?

Start screening at tdscreen.ai

Register for TDScreen now

Videra Health Launches TDScreen, a First-of-Its-Kind Video-based, AI-powered Tool to Assess Tardive Dyskinesia Symptoms

TDScreen AI-powered TD screening interface showing video analysis of patient movements for tardive dyskinesia detection

New study published in the Journal of Clinical Psychiatry reveals AI enables efficient, accurate and scalable detection of TD, representing a significant advancement in meeting the standard of care for TD screening

Orem, UT, June 3, 2025 – Videra Health, a leading AI platform for behavioral health providers, has announced the launch of TDScreen, the first-ever automated, video-based AI solution on the market to screen for Tardive Dyskinesia (TD) symptoms. TD is a chronic, involuntary movement disorder that can develop as a side effect of long-term use of certain medications, particularly antipsychotic drugs. While TDScreen isn’t intended as a standalone diagnostic tool, it represents a significant advancement in meeting the standard of care for TD screening.

TD presents unique screening challenges even for experienced clinicians and remains underdiagnosed. TD affects up to 2.6 million Americans, and up to 7 million Americans taking antipsychotic medications could develop TD symptoms. With its involuntary movements often mistaken for nervousness, aging, or other conditions, the gap in recognition represents not just a clinical challenge, but a deeply human one that affects quality of life and treatment outcomes. A paper published Wednesday in The Journal of Clinical Psychiatry, led by Principal Investigator Dr. Anthony Sterns and members of the iRxReminder and Videra Health teams, reveals that video-based AI enables efficient, accurate, and scalable detection of TD. This application has the potential to significantly improve early diagnosis and patient outcomes, especially in remote care settings where resources are scarcest. Videra Health’s TDScreen algorithm was built using the data from multiple studies, which was supported in part by the National Institute of Mental Health, and represents a significant leap forward in integrating artificial intelligence into psychiatric care, particularly in the era of telemedicine.

“Videra Health is thrilled to be able to launch a first-of-its-kind innovative solution to screen for TD symptoms, effectively,” said Loren Larsen, CEO of Videra Health. “TDScreen and our broader AI platform aren’t about replacing clinician judgment—they’re about enhancing it. By automating routine screenings, we free healthcare providers to focus on what matters most: the human connections and complex decision-making that drive quality care.” Larsen added, “We are grateful for the multiple academic and research partners who have contributed their time and expertise to these studies.”

“Early detection of TD is critical to mitigating its debilitating effects,” said Dr. Anthony A. Sterns, Ph.D., lead researcher on the project and CEO at iRxReminder. “Our AI-driven approach not only matches but exceeds human expert performance, offering a scalable solution to a major unmet clinical need,” added Dr. Joel W. Hughes, Ph.D., collaborator from Kent State University.

“As a physician who both treats –and lives with– tardive dyskinesia, this research marks a turning point for millions of patients who have been forced to wonder if the movement disorder they suffer from could be treatable,” says Owen S, Muir, M.D., CMO of iRxReminder, CMO and co-founder of Radial Health, and co-author of the publication.  “Now, physicians have a simple, evidence-based AI-guided tool to support their clinical decision making.”

TDScreen was validated across three clinical studies involving more than 350 participants on antipsychotic medications. The innovative AI tool developed by Videra Health utilizes advanced video analysis and a vision transformer machine learning architecture to detect TD with unprecedented accuracy. TDScreen demonstrates a Cohen’s Kappa of 0.61—a number indicating the algorithm is outperforming even calibrated human raters. The algorithm achieved an area under the receiver-operating-characteristic curve (AUC) of 0.89, surpassing the sensitivity and specificity of trained human raters using the standard Abnormal Involuntary Movement Scale (AIMS).

These numbers represent more than just statistical achievements—they translate to real-world benefits:

  • Consistency: Unlike human raters whose assessments may vary, AI provides the same evaluation standards every time
  • Accessibility: Patients can complete assessments from home on their own devices
  • Efficiency: Providers save valuable clinical time while increasing screening frequency
  • Earlier detection: Subtle symptoms can be identified before they become pronounced

Continuous monitoring: Regular assessments track symptom progression or improvement

With TDScreen, patients on antipsychotics can easily complete video-based screenings in-office or remotely, and enable providers to monitor or modify their treatment plans. The TDScreen tool is based on the Abnormal Involuntary Movement Scale (AIMS), a comprehensive clinician-rated scale designed to specifically evaluate involuntary movements. Employing advanced AI video technology, TDScreen efficiently assesses and quantifies the risk of TD in less than 5 minutes. The resulting score generated by this assessment can aid in clinical decision-making and management strategies.

TDscreen is available free of charge for any provider or patient wanting to screen for TD. Visit tdscreen.ai to learn more.

About Videra Health™

Videra Health is a leading AI platform for behavioral health providers and proactively identifies, triages and monitors at-risk patients using linguistic, audio and video analysis. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems. 

For more information, visit www.viderahealth.com.

About iRxReminder
iRxReminder specializes in digital health solutions aimed at enhancing medication adherence and mental health management through cutting-edge technology applications and innovative behavioral science solutions.

For more information, visit www.irxreminder.com.

Introducing Videra Sidekick Notes’s New Group Notes Feature

Videra Health

I’m thrilled to announce the release of our newest innovation in clinical documentation: Group Notes capability within our Sidekick Notes product. This groundbreaking feature addresses one of the most significant pain points in behavioral health – the time-consuming and complex process of documenting group therapy sessions.

The Challenge of Group Documentation

Throughout my conversations with clinicians across the country, one consistent theme emerges: group session documentation is uniquely challenging. Tracking multiple participants, capturing individual contributions, and creating comprehensive yet individualized notes has historically been a manual, time-intensive process that pulls providers away from what matters most – patient care.

Group therapy is a vital treatment modality, but its unique documentation requirements have often overburden clinicians causing inconsistent quality and accuracy. Until now.

Revolutionary AI-Powered Group Notes

Videra’s Sidekick Notes now includes the industry’s first-of-its-kind AI-powered group therapy documentation solution. This exclusive capability automatically:

  • Identifies individual speakers using our proprietary Speaker Map technology
  • Generates comprehensive session summaries that capture the overall group dynamic
  • Creates individualized sections for each participant
  • Provides speaker identification assistance for participants it cannot automatically recognize

What makes this particularly exciting is that we’ve designed the system to work alongside clinicians rather than replace their judgment. When our AI identifies a speaker with high confidence, it will label them accordingly with a visual indicator showing it was AI-assisted. For speakers it cannot identify with certainty, Sidekick presents the provider with small audio clips to confirm identification, ensuring accuracy while saving substantial time.

Beyond Just Group Notes

While Group Notes is the highlight of this release, Sidekick Notes continues to offer comprehensive documentation support for individual sessions across multiple note formats:

  • SOAP notes
  • DAP notes
  • GIRP notes

All with customizable tone settings (progress notes or medical necessity) and seamless integration with your existing workflows through several deployment methods, including browser-window based, browser-extension based, or Zoom integration.

The Impact on Provider Well-being

We built Sidekick because we believe documentation should support clinical care, not detract from it. By automating the most time-consuming aspects of this process – particularly for group sessions – we’re giving clinicians back valuable time to focus on patient care or personal well-being, saving 60-70% of their documentation time.

One early adopter of Group Notes told us: “I used to spend my evenings catching up on group documentation. With Sidekick Group Notes, I’m finishing my notes before I leave the office.”

Looking Forward

This release represents a significant milestone in our journey to transform behavioral healthcare technology. Our Speaker Map technology provides a first-of-its-kind ability to automatically identify each user based on their voice alone. Not more manually noting an entire session. Speaker Map does it for you.

In the coming months, we’ll continue enhancing our group documentation capabilities while expanding our Sidekick suite to include more tools that empower clinicians and improve patient care.

I invite you to experience Sidekick Notes and the new Group Notes feature firsthand. If you want to see Group Notes in action, make an appointment here for a demonstration, and join us in our mission to give clinicians more time for what matters most – helping people live healthier lives.

Together, we’re making the future of behavioral healthcare more human.

Can't get enough on AI, behavioral health, and life sciences? Head over to our blog for more.

More blog posts

Videra Health Launches TDScreen, a First-of-Its-Kind AI-powered Tool to Assess Tardive Dyskinesia Risk in Less Than Five Minutes

TDScreen will be accessible to National Council for Mental Wellbeing Members at no cost

Orem, Utah – April 28, 2025 – Videra Health™, a leading AI platform for behavioral health providers, has announced the launch of TDScreen, the first-ever automated, video based, AI solution on the market to screen for Tardive Dyskinesia (TD) risk, a chronic, involuntary movement disorder that can develop as a side effect of long-term use of certain medications, particularly antipsychotic drugs. National Council for Mental Wellbeing Members, a membership organization that drives policy and social change on behalf of more than 3,400 mental health and substance use treatment organizations and the more than 10 million children, adults and families they serve, will now have access to TDScreen at no cost.

TD presents unique screening challenges even for experienced clinicians and remains underdiagnosed despite affecting millions of Americans taking antipsychotic medications. With its involuntary movements often mistaken for nervousness, aging, or other conditions, the gap in recognition represents not just a clinical challenge, but a deeply human one that affects quality of life and treatment outcomes.

“Videra Health is thrilled to be able to launch a first-of-its-kind innovative solution to screen for TD risk, effectively,” said Loren Larsen, CEO of Videra Health. “TDScreen and our broader AI platform aren’t about replacing clinician judgment—they’re about enhancing it. By automating routine screenings, we free healthcare providers to focus on what matters most: the human connections and complex decision-making that drive quality care. Larsen added, “We are delighted to offer TDScreen to the National Council for Wellbeing Members, an important organization leading policy in mental health. ” 

“We’re proud to partner with Videra Health to provide TDScreen at no cost to our 3,200+ member organizations,” said Charles Ingoglia, president and CEO of the National Council for Mental Wellbeing. “This AI tool helps close the gap in detecting Tardive Dyskinesia, enabling earlier intervention and better outcomes. It’s a strong step forward in using technology to enhance mental health care.”

TDScreen uses advanced video analysis technology to evaluate patients for potential TD symptoms quickly and efficiently. With TDScreen, patients on antipsychotics can easily complete virtual screenings to accurately assess their risk factors in their own environments and enable providers to monitor or modify their treatment plans. The TDScreen tool is based on the Abnormal Involuntary Movement Scale (AIMS), a comprehensive clinician-rated scale designed to specifically evaluate involuntary movements. Employing advanced AI video technology, TDScreen efficiently assesses and quantifies the risk of TD in less than 5 minutes. The resulting score generated by this assessment can aid in clinical decision-making and management strategies.

Additional benefits of TD Screen include:

  • Providers can effortlessly enroll their patients who are receiving antipsychotics for automated TDScreen assessments at predetermined intervals, ensuring proactive and consistent healthcare management.
  • An intuitive interface simplifies scheduling tailored screening and monitoring protocols, accompanied by automated reminders and notifications to keep both providers and patients engaged every step of the way.

To learn more about TDScreen visit www.tdscreen.ai.

About Videra Health™

Videra Health is a leading AI-driven patient engagement and health assessment platform that empowers providers and healthcare organizations to proactively identify, triage, and monitor patients, closing care gaps using linguistic, audio and video analysis at scale. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems.

For more information, visit www.viderahealth.com.

About National Council for Mental Wellbeing

The National Council for Mental Wellbeing is a membership organization that drives policy and social change on behalf of more than 3,200 mental health and substance use treatment organizations and the more than 10 million children, adults and families they serve. We advocate for policies to ensure access to high-quality services. We build the capacity of mental health and substance use treatment organizations. And we promote greater understanding of mental wellbeing as a core component of comprehensive health and health care. Through our Mental Health First Aid (MHFA) program, we have trained more than 3 million people in the U.S. to identify, understand and respond to signs and symptoms of mental health and substance use challenges.

For more information, please visit https://www.thenationalcouncil.org. 

###

Media Contact:
Videra Health
Stacy Callahan
stacy@astonishmediagroup.com 

The Critical Role of Model Cards When Selecting an AI Vendor for Behavioral Health and Pharma

Model cards for AI vendors showing performance metrics across populations

In today’s healthcare landscape, model cards for AI vendors have become essential documentation when selecting technology partners for behavioral health and pharmaceutical applications. These comprehensive documents provide transparent details about AI models’ performance, training data, and limitations—critical information for healthcare organizations making high-stakes technology decisions that impact patient care.

What Are Model Cards and Why Do They Matter?

Model cards serve as transparent documentation for machine learning models, detailing their performance characteristics, training data, intended use cases, and limitations. First proposed by researchers at Google in 2019, model cards have quickly become a best practice in responsible AI development.

For behavioral health and pharmaceutical applications, where decisions directly impact patient care, model cards aren’t just nice-to-have documentation—they’re essential safeguards that provide critical information about the algorithms making or supporting clinical decisions.

Key Elements of Strong Model Cards in Healthcare AI

When evaluating AI vendors for behavioral health or pharmaceutical applications, look for model cards that include:

  • Intended Use and Clinical Context: Clear explanation of what the model is designed to do, and importantly, what it’s not designed to do.
  • Training Data Demographics: Details about the populations represented in the training data—particularly important for ensuring models work across diverse patient populations.
  • Performance Metrics: Specificity and sensitivity measurements, both overall and for specific demographic groups.
  • Validation Methodology: How the model was validated, including any peer-reviewed research or clinical studies.
  • Limitations and Constraints: Transparent acknowledgment of the model’s limitations and potential failure modes.
  • Bias Evaluation: Assessment of potential biases in the model and steps taken to mitigate them.
  • Regulatory Status: Information about FDA registration or other regulatory frameworks the model complies with.

Real-World Example: Behavioral Health Assessment Models

Consider a vendor offering AI models that analyze video responses to detect signs of depression. A comprehensive model card would specify:

  • The model predicts PHQ-9 equivalent scores based on facial expressions, voice tone, and natural language analysis
  • Training included data from 10,000+ individuals across diverse demographic groups
  • Overall accuracy metrics (e.g., AUC: 0.89) with breakdowns for different populations
  • Independent validation through IRB-approved studies
  • Lower accuracy rates for certain populations with smaller representation in training data
  • Not intended for standalone diagnosis, but as a screening aid for clinicians

This level of transparency enables healthcare organizations to make informed decisions about whether a particular AI solution aligns with their clinical needs, patient populations, and ethical standards.

The Coalition for Health AI (CHAI) produced a great example of what a model card can contain to ensure transparency, safety, security & privacy, fairness & bias, and usefulness. Individual model cards will look different, but the frameworks CHAI developed are a baseline.

The Regulatory Landscape and Model Documentation

As regulatory bodies like the FDA develop frameworks for AI as medical devices, comprehensive documentation is becoming increasingly important. The FDA’s proposed regulatory framework for AI/ML-based Software as a Medical Device (SaMD) emphasizes the importance of transparency in model development and performance.

For pharmaceutical companies, model documentation is particularly crucial for clinical trials, where regulators require clear evidence of model validity and reliability. Strong model cards can help satisfy these requirements and build trust with regulatory agencies.

Questions to Ask AI Vendors About Their Models

When evaluating AI vendors for behavioral health or pharmaceutical applications, consider asking:

  • “Can you provide detailed model cards for each of your algorithms?”
  • “How was your model validated across different demographic groups?”
  • “What peer-reviewed research supports the effectiveness of your model?”
  • “What are the known limitations or potential biases in your model?”
  • “How often is your model updated, and what is your validation process for new versions?”

Model Cards as a Competitive Advantage

As the AI healthcare market becomes increasingly competitive, comprehensive model cards aren’t just good practice—they’re becoming a competitive advantage. Organizations that prioritize vendors with thorough, transparent documentation are better positioned to implement AI solutions that are effective, ethical, and aligned with regulatory requirements.

When selecting an AI vendor for behavioral health or pharmaceutical applications, remember that the quality of their model cards often reflects the quality of their approach to AI development. In a field where decisions impact patient lives, this level of transparency isn’t optional—it’s essential.

By demanding comprehensive model cards from AI vendors, healthcare organizations can make more informed decisions, reduce implementation risks, and ultimately deliver better care to the patients who need it most.

Want more? Visit our blog page for the latest in AI across the healthcare industry.

Take me to the blog

Videra Health Partners with North South Consulting Group to Help Prevent Suicide-Related Deaths of Service Members

Orem, Utah – October 1, 2024 – Videra Health, a leading AI-driven, end-to-end clinical operations solution, has announced a partnership with North South Consulting Group (NSCG), to help prevent suicide-related deaths of service members. The announcement comes as suicide-related deaths among military service members have risen by 37% over the last 20 years.

Through the use of a mobile phone or computer, Videra Health’s groundbreaking technology uses AI and machine learning algorithms to analyze video data. The AI detects subtle changes in facial expressions, body movements, language, and speech patterns that could indicate the risk of mental health conditions and can proactively identify individuals at a higher risk of suicide. This real-time detection ability results in immediate mental health interventions for service members and can ultimately save lives.

“Our goal at Videra Health is to use AI not just as a tool, but as a force for good in supporting the mental health of those who risk their lives for our country,” says Videra Health CEO & Co-Founder Loren Larsen. “We’re honored to work alongside North South Consulting Group in this important mission, providing service members with access to early effective interventions that can prevent tragedy and promote long-term wellness.”

In August, representatives from NSCG and Videra Health spoke at the Kentucky State Capitol’s Interim Joint Committee on Veterans, Military Affairs & Public Protection to address the challenges and risks associated with suicide-related deaths of service members.

“North South Consulting Group is a Veteran-owned and -led business which is passionate about supporting servicemembers and their families,” said Krista Stevans, CEO and President of North South Consulting Group “We take every opportunity to fight military suicide through the services we provide to our clients. Our partnership with Videra Health is another avenue to help the military using enhanced data insights.“

Recent data suggests that the younger population of today’s military are more apt to engage with clinicians and therapists via mobile devices and platforms than they would in a face-to-face or clinical setting. The data emphasizes the importance of identifying those in need of care and affording them with appropriate resources when they need them the most.

About Videra Health™

Videra Health is a leading AI-driven patient engagement and health assessment platform that empowers providers and healthcare organizations to proactively identify, triage, and monitor patients, closing care gaps using linguistic, audio and video analysis at scale. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems. For more information, visit www.viderahealth.com.

###

Media Contact:
Videra Health
Stacy Callahan
stacy@astonishmediagroup.com

Videra Health Forms Advisory Board to Guide Continued Growth and Impact as a Leader in AI-driven Patient Engagement

Orem, Utah – July 31, 2024 – Videra Health™, a leading AI-driven clinical patient health assessment platform that empowers providers and healthcare organizations to proactively identify, triage, and monitor at-risk patients and close care gaps using linguistic, audio and video analysis, announced today the formation of its esteemed Advisory Board. 

“This distinguished group of top leaders brings a wealth of experience across healthcare technology, mental health, and business strategy to guide Videra Health’s continued growth and impact,” says Loren Larsen CEO of Videra Health. “Their insights will be crucial as we continue to innovate and empower care providers to ‘see’ their patients beyond traditional methods, ultimately improving mental health outcomes and expanding access to care.”

Already recognized by customers as the top mental health screening platform, the newly formed advisory board will be instrumental in guiding the company as it expands and continues to drive growth. Each member of the advisory board brings a wealth of experience that will be key to Videra Health as the company continues to set the industry standard in the mental health market.

Videra Health’s Advisory Board Members Include:

  • Amir Lahav, a Digital Health Advisor and a leading innovator at the forefront of clinical research. With more than 20 years of clinical experience, Amir is on a mission to bring together the brightest minds from far-ranging disciplines to push the boundaries of AI-driven solutions in clinical research and medicine. 
  • Chris Klomp, the former CEO of Collective Medical with a proven track record of building and scaling across healthtech. Chris was previously with Bain & Co and Bain Capital for many years. He is currently a board director and advisor to multiple healthcare organizations including Nomi Health, Maven Clinic, and InnovaCare Health, and is a commissioner of the Utah Digital Health Services Commission.
  • Owen Scott Muir, M.D., DFAACAP,  a dual board Certified child and general psychiatrist and distinguished fellow of the American Academy of Child and adolescent psychiatry.  Dr. Muir is an international speaker, Chief medical officer of iRxReminder, Fermata, and SVP, at Acacia Clinics, and a prolific best-selling author of both popular press and scientific work focusing on AI diagnostics and treatment resistant conditions. 
  • Wylie van den Akker, a seasoned software engineer with expertise in machine learning and data security. Wylie co-founded Collective Medical and served as VP of Innovation at PointClickCare. He brings a unique blend of technical and business acumen to Videra Health, optimizing the technology platform and helping with technical integrations.

“AI is already impacting healthcare, and Videra is on the bleeding edge of how we can use this technology to more safely, proactively, scalably, and inexpensively improve both patient care and the provider experience,” shared Chris Klomp, advisor to Videra. “Videra stands out not only for their innovative use of AI in health detection–utilizing deep data insights to deliver tailored and seamless care experiences to patients and the providers who serve them–but in how they do so by putting patient safety and privacy at the forefront of their efforts. I am deeply passionate about this area and excited to contribute to Videra Health’s mission.”

The formation of the advisory board underscores the company’s commitment to continuous innovation and excellence. With the guidance of these distinguished leaders, Videra Health is poised to set new standards in mental health care, ensuring that more patients receive the critical support they need and deserve.

About Videra Health™

Videra Health is a leading AI-driven patient engagement and health assessment platform that empowers providers and healthcare organizations to proactively identify, triage, and monitor patients, closing care gaps using linguistic, audio and video analysis at scale. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems. For more information, visit www.viderahealth.com.

###

Media Contact:
Videra Health
Stacy Callahan
stacy@astonishmediagroup.com 

RamaOnHealthcare Q&A: Brett Talbot, CCO and Loren Larsen, CEO of Videra Health

Discover how Videra Health is transforming mental health care in this insightful Q&A with Loren Larsen, CEO, and Brett Talbot, Chief Clinical Officer. They explore the innovative use of AI and video technology in mental health assessments, highlighting the benefits of enhanced accuracy and accessibility. They also delve into how AI has the potential to benefit PTSD specifically. Learn about the challenges and breakthroughs shaping the future of mental health care. Read the full article here.

The Future of TD Screening is Here: AI Takes on Tardive Dyskinesia Detection

May 5-11, 2024 is Tardive Dyskinesia (TD) Awareness Week. This annual campaign is meant to raise awareness and understanding of TD, a neurological disorder that can result from long-term use of certain medications for mental health conditions. As an AI technology company committed to improving healthcare, we are excited to announce our latest innovation – TDScreen, an AI video screener for estimating risk of TD.

The Importance of Tardive Dyskinesia Awareness Week

Tardive Dyskinesia is a condition that causes involuntary and repetitive movements, such as lip smacking, tongue protrusion, and jaw movements. It can have a significant impact on the quality of life of those affected, causing embarrassment and social isolation. Yet, many people, including healthcare providers, are still unfamiliar with TD. This is why TD Awareness Week is crucial in bringing attention to this condition and promoting early detection and treatment.

The Need for Proactive Tardive Dyskinesia Identification

Traditionally, TD is diagnosed through a lengthy physical examination conducted by a healthcare provider using the Abnormal Involuntary Movement Scale (AIMS) that requires extensive training. However, this can be challenging for patients who are unable to visit a clinic regularly. As a result, TD may go undetected and untreated, leading to irreversible symptoms and further deterioration of overall health. This is where TDScreen comes in – providing a proactive and convenient solution for remotely estimating risk of TD.  When TD is identified early there are two FDA approved medications, valbenazine (Ingrezza®) and deutetrabenazine (Austedo®).

Introducing TDScreen: An AI Video Assessment

TDScreen harnesses the power of artificial intelligence to analyze video footage of patients for potential signs of TD. Through advanced algorithms, TDScreen is able to detect subtle and early signs of TD, even those that may go unnoticed by the human eye. This means that patients can be screened for TD from the comfort of their own home, without the need for in-person appointments.

How TDScreen Works

TDScreen is easy to use and requires no special equipment. All patients need is a smartphone, tablet, or laptop with a front-facing camera. The screening takes less than 5 minutes to complete and can be done in the comfort of their own home. Patients simply record themselves performing a series of movements and facial expressions while following instructions on the screen. The video is then securely uploaded to our platform for analysis.

The Benefits of TDScreen for Providers and Patients

For providers, TDScreen offers a way to stay ahead of TD, even with patients who are unable to visit the clinic regularly. By being proactive in identifying TD, providers can work towards early intervention and better outcomes for their patients. For patients, TDScreen provides a convenient and non-invasive way to get screened for TD without the need for frequent in-person appointments. It also offers peace of mind, knowing that they are being regularly monitored for potential signs of TD.

How Providers Can Use TDScreen During Tardive Dyskinesia Awareness Week

We encourage all providers, especially neurologists and psychiatrists, to take advantage of Tardive Dyskinesia Awareness Week and introduce TDScreen to their patients as a proactive tool for TD detection. We provide providers with a special identification code to share with their patients, allowing them to easily complete the TDScreen assessment and have their results automatically shared with the requesting provider.

TDScreen: Changing the Game in Remote Tardive Dyskinesia Screening

At our core, we are driven by our mission to improve healthcare outcomes through the use of innovative technologies like TDScreen. This TD Awareness Week, we are proud to offer an efficient and effective solution for remote TD risk detection, making it easier for providers to identify TD early and ultimately improve the lives of their patients. Join us in raising awareness for TD and taking a proactive approach to TD detection with TDScreen.

Recognizing support from iRx Reminder and NIMH funding (Grant No. 2R44MH114763).